GlassScriptPhysician profile
Suzanne M Skoog
NPI 1174598643
$3,724.18
in general payments reported to CMS, 2019-2025
26 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $298 · 2021: $310 · 2022: $212 · 2023: $741 · 2024: $1,013 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.68 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $458.92 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $364.70 | 2019-2024 | |
| Pfizer INC. | $229.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.24 | 2019-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $142.50 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $116.89 | 2020-2023 | Cimzia, Clenpiq |
| Janssen Biotech, INC. | $72.53 | 2023-2025 | Tremfya, Stelara, Remicade |
| Intercept Pharmaceuticals, INC. | $44.23 | 2024 | |
| Biocon Biologics INC | $43.88 | 2024-2025 | Hulio, Yesintek |
| Medtronic, INC. | $42.39 | 2024 | Interstim |
| Ipsen Biopharmaceuticals, INC | $40.14 | 2024 | Bylvay, Iqirvo |
| Celgene Corporation | $33.96 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $28.86 | 2023 | |
| Braintree Laboratories, INC. | $28.49 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.55 | 2019 | |
| Daiichi Sankyo INC. | $25.14 | 2025 | Injectafer |
| Celltrion USA INC. | $24.86 | 2024 | Vegzelma |
| Fresenius Kabi USA, LLC | $22.95 | 2024 | Idacio |
| Lucid Diagnostics INC. | $20.87 | 2025 | |
| Lilly USA, LLC | $19.40 | 2024 | Omvoh |
| Qol Medical, LLC | $16.32 | 2025 | Sucraid |
| Capsovision, INC. | $15.30 | 2023 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $14.76 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.34 | 2024 | Voquezna |
| Allergan, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Skoog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.